Apoptotic signalling targets the post-endocytic sorting machinery of the death receptor Fas/CD95.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 09 11 2016
accepted: 12 06 2019
entrez: 17 7 2019
pubmed: 17 7 2019
medline: 19 12 2019
Statut: epublish

Résumé

Fas plays a major role in regulating ligand-induced apoptosis in many cell types. It is well known that several cancers demonstrate reduced cell surface levels of Fas and thus escape a potential control system via ligand-induced apoptosis, although underlying mechanisms are unclear. Here we report that the endosome associated trafficking regulator 1 (ENTR1), controls cell surface levels of Fas and Fas-mediated apoptotic signalling. ENTR1 regulates, via binding to the coiled coil domain protein Dysbindin, the delivery of Fas from endosomes to lysosomes thereby controlling termination of Fas signal transduction. We demonstrate that ENTR1 is cleaved during Fas-induced apoptosis in a caspase-dependent manner revealing an unexpected interplay of apoptotic signalling and regulation of endolysosomal trafficking resulting in a positive feedback signalling-loop. Our data provide insights into the molecular mechanism of Fas post-endocytic trafficking and signalling, opening possible explanations on how cancer cells regulate cell surface levels of death receptors.

Identifiants

pubmed: 31308371
doi: 10.1038/s41467-019-11025-y
pii: 10.1038/s41467-019-11025-y
pmc: PMC6629679
doi:

Substances chimiques

Antigens, Neoplasm 0
Dysbindin 0
ENTR1 protein, human 0
Fas Ligand Protein 0
Intracellular Signaling Peptides and Proteins 0
Vesicular Transport Proteins 0
fas Receptor 0
PTPN13 protein, human EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 13 EC 3.1.3.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3105

Références

FEBS J. 2017 May;284(10):1394-1420
pubmed: 28371378
Oncogene. 2013 Oct 31;32(44):5220-32
pubmed: 23222715
J Neurooncol. 2005 Sep;74(3):241-8
pubmed: 16187021
J Cell Sci. 2014 Nov 15;127(Pt 22):4940-53
pubmed: 25278552
Br J Dermatol. 2000 Aug;143(2):307-12
pubmed: 10951137
Nat Commun. 2017 Mar 02;8:14613
pubmed: 28252024
Biochem J. 2006 May 1;395(3):587-98
pubmed: 16448387
Semin Cell Dev Biol. 2018 Feb;74:11-20
pubmed: 28797837
Sci Rep. 2016 Oct 21;6:35399
pubmed: 27767179
Nat Commun. 2013;4:2250
pubmed: 23907271
Prog Mol Subcell Biol. 2018;57:235-272
pubmed: 30097778
Cell Death Differ. 2003 Jan;10(1):26-35
pubmed: 12655293
Arch Biochem Biophys. 1996 Feb 1;326(1):64-72
pubmed: 8579373
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
PLoS One. 2010 Feb 19;5(2):e9325
pubmed: 20174469
Semin Cell Dev Biol. 2018 Feb;74:4-10
pubmed: 28797838
Exp Cell Res. 2008 Feb 15;314(4):801-13
pubmed: 18031739
Int J Cancer. 1998 May 29;76(5):652-8
pubmed: 9610721
Mol Cell. 2010 Jun 25;38(6):908-15
pubmed: 20620960
Mol Cell Biol. 2003 May;23(10):3623-35
pubmed: 12724420
Genome Res. 2005 Mar;15(3):376-84
pubmed: 15710747
Methods Enzymol. 2005;403:481-91
pubmed: 16473613
Am J Pathol. 2001 Apr;158(4):1335-44
pubmed: 11290551
Biochem J. 1997 Aug 15;326 ( Pt 1):1-16
pubmed: 9337844
J Exp Med. 1998 Feb 16;187(4):587-600
pubmed: 9463409
Nat Genet. 2003 Sep;35(1):84-9
pubmed: 12923531
Nat Rev Mol Cell Biol. 2002 Aug;3(8):600-14
pubmed: 12154371
J Neurochem. 2010 Jun;113(6):1491-503
pubmed: 20236384
Int J Oncol. 2001 Feb;18(2):311-6
pubmed: 11172597
BMB Rep. 2013 Dec;46(12):588-93
pubmed: 24195789
Oncotarget. 2018 May 25;9(40):25891-25902
pubmed: 29899829
Curr Opin Cell Biol. 2006 Oct;18(5):549-57
pubmed: 16904305
Cell. 2015 Jul 16;162(2):425-440
pubmed: 26186194
J Biol Chem. 2004 Nov 5;279(45):46415-23
pubmed: 15337758
Mol Cell. 2016 Feb 18;61(4):602-613
pubmed: 26853147
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Cancer Res. 1998 Apr 15;58(8):1741-9
pubmed: 9563493
Science. 2000 Jun 30;288(5475):2354-7
pubmed: 10875918
Science. 1995 Apr 21;268(5209):411-5
pubmed: 7536343
Mol Neurobiol. 2011 Aug;44(1):53-64
pubmed: 21520000
J Biol Chem. 1997 Mar 28;272(13):8539-45
pubmed: 9079683
J Pathol. 1999 Jun;188(2):207-12
pubmed: 10398166
IUBMB Life. 2000 Aug;50(2):85-90
pubmed: 11185963
Br J Cancer. 2004 Nov 1;91(9):1718-25
pubmed: 15494722
Mol Biol Cell. 2006 Aug;17(8):3469-83
pubmed: 16707569
J Biol Chem. 2006 Jan 20;281(3):1840-52
pubmed: 16306044
Curr Biol. 2014 Jul 21;24(14):1670-1676
pubmed: 24980502
Semin Immunol. 2003 Jun;15(3):185-93
pubmed: 14563117
J Cell Biol. 2004 Nov 22;167(4):735-44
pubmed: 15557123
J Cell Sci. 2001 Aug;114(Pt 15):2735-46
pubmed: 11683408
Nature. 1997 Jul 10;388(6638):190-5
pubmed: 9217161
Mol Biol Cell. 2004 Aug;15(8):3530-41
pubmed: 15181150
Trends Cell Biol. 2014 Jul;24(7):407-15
pubmed: 24675420
Differentiation. 2012 Mar;83(3):148-57
pubmed: 22364882
Cell Death Differ. 2003 Jan;10(1):144-5
pubmed: 12655304
Cell. 1997 Feb 7;88(3):355-65
pubmed: 9039262
ASN Neuro. 2011 May 27;3(2):
pubmed: 21504412
Histochem Cell Biol. 2010 Jan;133(1):41-55
pubmed: 19830447
Nat Rev Mol Cell Biol. 2009 Sep;10(9):609-22
pubmed: 19696798
EMBO J. 2006 Mar 8;25(5):1009-23
pubmed: 16498403
J Gastrointest Cancer. 2012 Jun;43(2):224-8
pubmed: 21271302
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Nat Rev Mol Cell Biol. 2018 Nov;19(11):679-696
pubmed: 30194414
DNA Cell Biol. 2005 Dec;24(12):777-85
pubmed: 16332174
Annu Rev Immunol. 2006;24:321-52
pubmed: 16551252
Int J Cancer. 2000 Aug 15;87(4):473-9
pubmed: 10918185
Oncogene. 2013 Sep 26;32(39):4602-13
pubmed: 23108400
Nat Commun. 2014 Aug 04;5:4556
pubmed: 25089012
Cell Death Differ. 2015 Apr;22(4):549-59
pubmed: 25656654

Auteurs

Shruti Sharma (S)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.

Antonio Carmona (A)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.

Agnieszka Skowronek (A)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.

Fangyan Yu (F)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Mark O Collins (MO)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.

Sindhu Naik (S)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.

Claire M Murzeau (CM)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.

Pei-Li Tseng (PL)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK.

Kai S Erdmann (KS)

Department of Biomedical Science & Centre of Membrane Interactions and Dynamics, University of Sheffield, Sheffield, S10 2TN, UK. k.erdmann@sheffield.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH